Skip to content

Public FDA record

Z-0604-2019: Binding Site Human IgM Kit (for SPAPLUS), REF: NK012.S The device consists of reaction buffer, sheep ant

Recall record Z-0604-2019 for The Binding Site Group, Ltd.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0604-2019
Company in FDA record
The Binding Site Group, Ltd.
FDA classification date
Dec 13, 2018
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Firm is offering advice to customers experiencing challenges when validating the calibration curve of the IgM kits. This is indicated by kit control values reporting outside the specified ranges.

Source facts

Action
On 11/06/2018, the firm, The Binding Site, emailed an "Urgent Medical Device Correction notice" and Field Correction E-back Form to customers. The notice described the product, problem and actions to be taken. Customers were instructed to do the following: 1) Reagents are to be loaded on-board the analyser and left for a minimum of 18 hours prior to running the calibration and validating the curve. Please leave the reagents on-board the analyser until empty. 2) Once calibration is established and validated, reagents must remain on the instrument until the reagent has been fully consumed. 3) When not in use the control vials and calibrator sets should be removed from the instrument, be capped to avoid evaporation and stored at 2-8 degrees C. 4) To be able to accept the calibration curve and to use the assay to report test results, the control materials to be tested at a minimum once a day should return results within 15% of the concentration(s) as stated on the accompanying QC certificate. If a control measurement is out of range when assayed with a stored curve the assay must be recalibrated. If on recalibration the control values measured with the new curve are still out of range, the instrument and the assay parameters should be checked before repeating the assay. 5) If calibration issues are still experienced when following this advice please do not hesitate to contact a firm representative. The E-back Form requests that each customer sign the form confirming they have both received and have followed the advice issued in the Notification; and return completed E-back form to technical.support@bindingsite.com or your local Binding Site Representative. This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. Customers with additional questions are encouraged to contact their local firm representative, or customer service via phon
Initiated
2018-11-06
Root cause
Under Investigation by firm
Terminated
2021-04-27
Distribution
U.S Distribution to states of: CA, IL, PA, FL, NE, WA, IN, NY, SD and VA,
Recall number
Z-0604-2019
Recall status
Terminated
CDRH record ID
168674
FDA classified
2018-12-13
Recall event number
81421

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗